Kosuke Matsuda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kosuke Matsuda has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Akihisa Ueno
Department of Pathology, School of Medicine, Tokai University, 143 Shimokasuya, Isehara 259-1193, Japan
20 shared publications - Hanako Tsujikawa
Department of Pathology, Keio University School of Medicine, Tokyo, Japan
20 shared publications - Hidenori Ojima
Department of Pathology, Keio University School of Medicine, Tokyo, Japan
20 shared publications - Hirohito Takeuchi
Department of Gastroenterology and Hepatology, Tokyo Medical University, Shinjuku-ku, Japan
20 shared publications - Kathryn Effendi
Department of Pathology, Keio University School of Medicine, Tokyo, Japan
20 shared publications - Katsutoshi Sugimoto
Department of Gastroenterology and Hepatology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan
20 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (39)
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation
The RNF43 p.G659fs ( RNF43 659mut ) mutation occurs in 8% of colorectal cancers (CRCs) and is enriched in microsatellite instability–high (MSI-H) tumors. Although RNF43 659mut promotes tumor growth through phosphatidylinositol 3-kinase/protein kinase B/mechanistic target of rapamycin (PI3K/AKT/mTOR) activation independent of WNT signaling, its immunologic effects are poorly defined. We show that RNF43 659mut shapes an immunosuppressive natural killer (NK) cell landscape in MSI-H CRC. Single-cell RNA sequencing and multiplex immunohistochemistry revealed increased NK cell infiltration in RNF43 659mut tumors, yet these cells displayed inhibitory phenotypes. Bulk RNA sequencing and flow cytometry of NK cells cocultured with RNF43 659mut isogenic lines and MSI-H patient-derived organoids demonstrated reduced functional NK subsets, decreased activation markers, increased inhibitory receptors, and impaired cytotoxicity. Mechanistically, RNF43 659mut -mediated PI3K/AKT activation induced HLA-E expression, suppressing NK cell function. Pharmacological or small interfering RNA–mediated PI3K/AKT inhibition restored NK cell activity and enhanced tumor cell killing. Spatial analysis of MSI-H patient tumors revealed close proximity between NKG2A + NK cells and HLA-E + tumor cells, which were themselves adjacent to PI3K/AKT-activated tumor cells, highlighting a localized immunosuppressive niche. These findings uncover an immune evasion mechanism in MSI-H CRC, implicating the PI3K/AKT-HLA-E/NKG2A axis as a promising therapeutic target to overcome immunotherapy resistance.
- 25 September 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (39)
Open AccessRNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation
The RNF43 p.G659fs ( RNF43 659mut ) mutation occurs in 8% of colorectal cancers (CRCs) and is enriched in microsatellite instability–high (MSI-H) tumors. Although RNF43 659mut promotes tumor growth through phosphatidylinositol 3-kinase/protein kinase B/mechanistic target of rapamycin (PI3K/AKT/mTOR) activation independent of WNT signaling, its immunologic effects are poorly defined. We show that RNF43 659mut shapes an immunosuppressive natural killer (NK) cell landscape in MSI-H CRC. Single-cell RNA sequencing and multiplex immunohistochemistry revealed increased NK cell infiltration in RNF43 659mut tumors, yet these cells displayed inhibitory phenotypes. Bulk RNA sequencing and flow cytometry of NK cells cocultured with RNF43 659mut isogenic lines and MSI-H patient-derived organoids demonstrated reduced functional NK subsets, decreased activation markers, increased inhibitory receptors, and impaired cytotoxicity. Mechanistically, RNF43 659mut -mediated PI3K/AKT activation induced HLA-E expression, suppressing NK cell function. Pharmacological or small interfering RNA–mediated PI3K/AKT inhibition restored NK cell activity and enhanced tumor cell killing. Spatial analysis of MSI-H patient tumors revealed close proximity between NKG2A + NK cells and HLA-E + tumor cells, which were themselves adjacent to PI3K/AKT-activated tumor cells, highlighting a localized immunosuppressive niche. These findings uncover an immune evasion mechanism in MSI-H CRC, implicating the PI3K/AKT-HLA-E/NKG2A axis as a promising therapeutic target to overcome immunotherapy resistance.
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Data from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Purpose:Immunotherapies have led to a paradigm shift in the treatment of hepatocellular carcinoma (HCC). Studies have revealed the single-cell catalogs of tumor-infiltrating immune cells and the trajectories of their differentiation. Nevertheless, the spatial distribution of these immune cells with distinct phenotypes in the tumor microenvironment and their clinicopathologic significance in resectable and unresectable HCCs are still largely unclear.Experimental Design:We analyzed the spatial dynamics of intratumoral CD4 and CD8 T cells and their association with B and plasma cells using 283 surgically resected HCC samples, 58 unresectable HCC samples before combined immunotherapy [atezolizumab plus bevacizumab (Atezo + Bev)], and autopsy specimens from 50 cases of advanced-stage HCC through multiplex IHC combined with transcriptomic and driver gene mutation analyses. Classification based on the spatial dynamics of T- and B-cell responses (refined immunosubtype) was developed, and its clinicopathologic significance was analyzed.Results:We found that stem-like CD4 and CD8 T cells were mainly observed in T-cell aggregates and T-cell zone of tertiary lymphoid structure (TLS). The differentiation of T follicular helper cells was associated with the development of TLS, whereas the differentiation of CXCL13-expressing CD4 TCXCL13 cells with a phenotype resembling T peripheral helper cells was associated with the development of the lymphoplasmacytic microenvironment. The refined immunosubtype could predict clinical outcomes of resectable HCC after surgery and unresectable HCC after Atezo + Bev therapy. The immune microenvironment of metastatic lesions tended to reflect those of primary lesions.Conclusions:We revealed the spatial dynamics of T- and B-cell responses in HCC, which is closely associated with the clinical outcome after surgical resection or Atezo + Bev therapy.
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Purpose:Immunotherapies have led to a paradigm shift in the treatment of hepatocellular carcinoma (HCC). Studies have revealed the single-cell catalogs of tumor-infiltrating immune cells and the trajectories of their differentiation. Nevertheless, the spatial distribution of these immune cells with distinct phenotypes in the tumor microenvironment and their clinicopathologic significance in resectable and unresectable HCCs are still largely unclear.Experimental Design:We analyzed the spatial dynamics of intratumoral CD4 and CD8 T cells and their association with B and plasma cells using 283 surgically resected HCC samples, 58 unresectable HCC samples before combined immunotherapy [atezolizumab plus bevacizumab (Atezo + Bev)], and autopsy specimens from 50 cases of advanced-stage HCC through multiplex IHC combined with transcriptomic and driver gene mutation analyses. Classification based on the spatial dynamics of T- and B-cell responses (refined immunosubtype) was developed, and its clinicopathologic significance was analyzed.Results:We found that stem-like CD4 and CD8 T cells were mainly observed in T-cell aggregates and T-cell zone of tertiary lymphoid structure (TLS). The differentiation of T follicular helper cells was associated with the development of TLS, whereas the differentiation of CXCL13-expressing CD4 TCXCL13 cells with a phenotype resembling T peripheral helper cells was associated with the development of the lymphoplasmacytic microenvironment. The refined immunosubtype could predict clinical outcomes of resectable HCC after surgery and unresectable HCC after Atezo + Bev therapy. The immune microenvironment of metastatic lesions tended to reflect those of primary lesions.Conclusions:We revealed the spatial dynamics of T- and B-cell responses in HCC, which is closely associated with the clinical outcome after surgical resection or Atezo + Bev therapy.
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Table S4. Clinicopathological findings in cases treated with Atezo+Bev therapy
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Table S4. Clinicopathological findings in cases treated with Atezo+Bev therapy
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Figure S2. Example of histocytometric analysis
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Figure S2. Example of histocytometric analysis
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Figure S5. Intratumoral distribution of NK cells
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Figure S5. Intratumoral distribution of NK cells
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Table S3. Multivariate analysis for DFS in Cohort 1 + 2 (n = 268)
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Table S3. Multivariate analysis for DFS in Cohort 1 + 2 (n = 268)
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Figure S7. CD68+ and CD169+ macrophages in TA/TLS
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Figure S7. CD68+ and CD169+ macrophages in TA/TLS
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Table S6. Clinicopathological findings in autopsy cases.
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Table S6. Clinicopathological findings in autopsy cases.
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Figure S4. TCF1 expression in TA and TLS
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Figure S4. TCF1 expression in TA and TLS
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Figure S6. CXCL13 expression in TA and TLS
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Figure S6. CXCL13 expression in TA and TLS